Premium
Rhizolutin, a Novel 7/10/6‐Tricyclic Dilactone, Dissociates Misfolded Protein Aggregates and Reduces Apoptosis/Inflammation Associated with Alzheimer's Disease
Author(s) -
Kwon Yun,
Shin Jisu,
Nam Kwangho,
An Joon Soo,
Yang SeungHoon,
Hong SeongHeon,
Bae Munhyung,
Moon Kyuho,
Cho Yakdol,
Woo Jiwan,
Park Keunwan,
Kim Kyeonghwan,
Shin Jongheon,
Kim ByungYong,
Kim YoungSoo,
Oh DongChan
Publication year - 2020
Publication title -
angewandte chemie
Language(s) - English
Resource type - Journals
eISSN - 1521-3757
pISSN - 0044-8249
DOI - 10.1002/ange.202009294
Subject(s) - tricyclic , chemistry , natural product , inflammation , apoptosis , in vitro , in vivo , tau protein , alzheimer's disease , microbiology and biotechnology , disease , biochemistry , stereochemistry , biology , medicine , pathology , immunology
Rhizolutin ( 1 ) was discovered as a natural product of ginseng‐rhizospheric Streptomyces sp. WON17. Its structure features an unprecedented 7/10/6‐tricyclic dilactone carbon skeleton composed of dimethylcyclodecatriene flanked by a 7‐membered and a 6‐membered lactone ring based on spectroscopic analysis. During an unbiased screening of natural product libraries, this novel compound was found to dissociate amyloid‐β (Aβ) plaques and tau tangles, which are key pathological hallmarks of Alzheimer's disease (AD). Rhizolutin treatment of APP/PS1 double transgenic mice with AD significantly dissociated hippocampal plaques. In vitro, rhizolutin substantially decreased Aβ‐induced apoptosis and inflammation in neuronal and glial cells. Our findings introduce a unique chemical entity that targets Aβ and tau concurrently by mimicking misfolded protein clearance mechanisms of immunotherapy, which is prominently investigated in clinical trials.